Buy SciVac (SVACF), Now for a potential Gain of more than, 1328%

Immediate BUY Opportunity!

Ticker symbol


Price Range

$0.16 - $0.19

52 Week High


Potential Profit


“SciVac intends to pursue marketing approvals for Sci-B-Vac in the United States and other territories worldwide, initially focusing on at-risk populations such as End-Stage Renal Disease and HIV patients.” Dr. Phillip Frost, Chairman and CEO, Opko Health

SVACF: Imagine investing in the successful eradication of a global pandemic killer

In 1798, Edward Jenner developed the world’s first ever vaccine. It was against the small pox virus and helped successfully eradicate that scourge from the face of the Earth.

If you had the chance to go back in time to 1798 and invest in Edward Jenner’s small pox vaccine, how rich do you think you’d be?

Let’s get a little more realistic though. If you had the chance to go back in time to 1952 and invest in Dr. Jonas Salk’s polio vaccine, how rich do you think you’d be today?

Forbes has thankfully answered that question for us. By sheer generosity and human kindness, Salk decided not to patent his world-changing polio vaccine that helped mostly eradicate the dreaded paralyzing disease from the globe. He wanted the polio virus defeated as quickly as possible and as cheaply as possible, profits be damned. And he got his wish.

But had Salk chosen to patent his vaccine,
he would have made $7 billion.

A $500 investment in "SVACF" could turn into $1,560! And a $5000 investment in "SVACF" could turn into $15,600!!!

Had you been a shareholder, your gains would have been SPECTACULAR.

But dreaming about going back in time is a fool’s calculus. What I’m going to show you as an investor is the next small pox vaccine, the next polio vaccine, the next world-changing vaccine to eradicate a horrible scourge off the face of the Earth forever.
And this time, you can get in on it. Without fantasy. Without a time machine. All you need to do is read this report.
And then you need to act fast, because there isn’t much time until this vaccine is discovered by some very big players on Wall Street.

SVACF Imagine investing in the successful eradication of a global pandemic killer The current standard of care vaccine for hepatitis B is sold by Big Pharma Giant GlaxoSmithKline (GSK). It’s called Engerix, and it sold over $1B just last year alone.

In fact, Engerix was the world’s sixth best selling vaccine in 2013. The only problem is, as mentioned, it is only 90% effective. Let’s do some math. 240 million people carry HBV today, with a 90% effective vaccine already available. That means if there were no vaccine available at all, then close to one third of the world’s entire population would be carrying HBV right now.

By current mortality rates, this would have led to over 6 million deaths per year.

I’m going to tell you about this vaccine, what it is, how it works, and of course which company developed it and how to invest. But first, I want you to think of the world’s scariest, deadliest, most infectious diseases. You’re probably thinking of the incurable ones like HIV, ebola, or the H1N1 avian flu. But none of those three can hold a candle to plain old hepatitis.

In 2014, there were just over 15,000 confirmed cases of ebola globally. 11,000 deaths were recorded. Today, there are over 37 million people in the world who are infected with HIV. This year 1.2 million deaths were recorded.

In the world today, there are over 400 million people infected with hepatitis in all its forms. Last year, 1.3 million hepatitis deaths were recorded. And the world’s deadliest form of hepatitis, by infections and deaths per year, is by far hepatitis B, with over 240 million infections and 780,000 deaths a year.

Now, there is already a hepatitis B vaccine available, but it is only 90% effective. A new, better vaccine that is already proven 100% effective on newborns has been successfully developed by a company called SciVac (SVACF), and that is the investment I want to tell you about today.

Dr Dinesh Kini “Hepatitis B is 100 times more infectious than HIV.”

A $500 investment in "SVACF" could turn into $1,560! And a $5000 investment in "SVACF" could turn into $15,600!!!

Fortunately, Glaxo’s blockbuster HBV vaccine is pretty effective. The problem is, it is not nearly effective enough, and millions of people are still dying.

The new game-changing vaccine that I’m talking about is a new third generation hepatitis B (HBV) vaccine – SciVac’s Sci-B-Vac. It works, it is already approved in 10 countries throughout the world, and it is proven 98% effective. But the news that will send a shiver down your spine is that it has been shown to be 100% effective on newborns.

Sci-B-Vac is not some speculative product that could hopefully one day change the world and eradicate HBV.

Sci-B-Vac was developed in Israel by SciVac Therapeutics (SVACF). Investors in SciVac today are in virtually the same position as Jonas Salk would have been in 1952 had he simply patented the polio vaccine. Now I love making money with the right stock picks. I’m sure you do as well. And I love helping other people make money, too. That’s why I write these reports. SVACF is sure to make me a whole lot richer. But there is something extra special about investing in the product that will literally save millions of people over the next few years.

It’s great to make money. But it’s even greater to be a part of something that will change the world and save lives. I’m sure you agree. If this is indeed the case, then why have so precious few have even heard of SciVac?


Immediate BUY Opportunity!

Ticker symbol


Price Range

$0.16 - $0.19

52 Week High


Potential Profit


100% effective on newborn babies. Think about what that means for a second.

It means that Sci-B-Vac has the potential to wipe the hepatitis B scourge right off the face of the Earth.

Just like small pox and polio have been eradicated, so too will HBV. Once this vaccine is approved globally, millions of innocent people will be saved every year. And yes – some people are going to make a LOT of money.

For two simple reasons. First, because Sci-B-Vac is not yet approved in the US, the world’s biggest pharmaceutical hub. Second, Sci-B-Vac was developed originally by a private Israeli company with zero Wall Street presence or public listing anywhere.

But all of that is changing. Fast.

Just one short month ago, SciVac was brought public by one of biotech’s most famous big players. On August 5, former Chairman of Teva Pharmaceuticals (TEVA) and current CEO and Chaiman of Opko Health (OPK) Phillip Frost closed a deal with SciVac that brought it public and immediately available to investors under the symbol SVACF.

Frost had already owned 45% of SciVac through Opko’s private equity investments before this move. What the IPO now signifies is that SciVac’s world-changing HBV vaccine is about to hit prime time, and Frost has positioned himself to benefit.

So how does Sci-B-Vac™ work, and how is it different from Glaxo’s blockbuster Engerix?
Engerix and other current standard-of-care HBV vaccines are created using yeast cells. These yeast cells are used to display a single antigen that is on the HBV protein coat. In 90% of cases, the immune system is successfully tricked into thinking that this yeast cell is a pathogen and attacks the antigen, creating immunity to HBV in the process.

But in 10% of cases, the immune system doesn’t fall for it, and no immunity results.
This is especially true for HIV patients, other patients with weakened immune systems, and patients with end stage kidney failure. These patient groups are the most at risk for HBV infection, even with current available vaccines.

The issue with Engerix is that HBV actually contains 3 antigens on its coat. If a vaccine against hepatitis B is going to be 100% effective, it needs to contain all 3 antigens. Not just one.
Sci-B-Vac™ contains all 3 antigens.

A $500 investment in "SVACF" could turn into $1,560! And a $5000 investment in "SVACF" could turn into $15,600!!!

Immediate BUY Opportunity!

Ticker symbol


Price Range

$0.16 - $0.19

52 Week High


Potential Profit


Having all 3 antigens is not Sci-B-Vac™’s only advantage. The other crucial difference is that Sci-B-Vac™ is derived from mammalian cells instead of yeast cells, enabling the immune system to recognize them much better. In almost all cases, immunity against HBV results.

“SciVac intends to pursue marketing approvals for Sci-B-Vac in the United States and other territories worldwide, initially focusing on at-risk populations such as End-Stage Renal Disease and HIV patients.” Dr. Phillip Frost, Chairman and CEO, Opko Health

I firmly believe that once Sci-B-Vac breaks through the US market on FDA approval, that it could easily become the new standard of care for HBV worldwide. After all, who wants to take a vaccine that is only 90% effective against a fatal disease when you can have a 100% effective vaccine for close to the same price?


We’re not talking years and years of development here. SciVac plans to meet with the FDA by early next year, and go directly to a pivotal phase 3 trial.

And based on what we’ve seen already with data in other countries on over 5,000 patients, there is virtually no chance that these trials won’t succeed.

Now let’s do some math. SVACF currently has a market cap of about $150 million with current sales of about $10M a year in vaccine. If Sci-B-Vac™ successfully penetrates Glaxo’s Engerix market of over $1B a year to the tune of even 30%, that translates to $300M in sales annually.

That’s an increase of 30x in the next few years, at least.

A concurrent increase in market cap a $1,000 in SVACF today could be worth $30,000 in just a few years.

And that’s assuming no premium at all on SVACF shares. Investors in hepatitis vaccines should also know one critical thing. Hepatitis medications are currently one of the hottest franchises in all of biotech. That means, when word really gets out of SciVac’s upcoming phase 3 HBV trials, Wall Street biotech investors could go crazy.

Here are just a few examples.

In 2011, Gilead Sciences (GILD) bought Pharmasset for a whopping $11B, just in order to get access to its hepatitis C pipeline.
This year, it seems that gargantuan $11B price tag was worth it, as Gilead’s two key hepatitis drugs Sovaldi and Harvoni generated nearly $5B in sales – and that’s only a single year! Last year, Merck and Co. (MRK) acquired Idenix for $3.85B for the same reason, and now analysts believe that Merck can make a serious dent in Gilead’s huge market!

Immediate BUY Opportunity!

Ticker symbol


Price Range

$0.16 - $0.19

52 Week High


Potential Profit


But as many billions upon billions of dollars that hepatitis C medications rake in every year, and as excited as Wall Street is about the space, the simple fact is that hepatitis B infects and kills MANY more people every year than hepatitis C.

HCV “only” kills 500,000 annually. HBV takes the lives of 780,000 people every single year. And while HCV antiviral medications can control the disease in 90% of cases, SciVac’s HBV vaccine can eliminate the disease and wipe it off the face of the planet for good.

There is a reason that the Warren Buffet of biotech went public with SciVac specifically now. He knows something. He should, since he owns 30% of the company.

At the very least, we could be looking at a 30x increase. That’s 3,000%, just assuming a 30% market penetration of the current standard of care for hepatitis B.

Now, just imagine what could be if Sci-B-Vac becomes the new standard of care?

I won’t even calculate the numbers.

It’s 1798. You’re Edward Jenner, and you’re about to eradicate small pox from the planet.

It’s 1952. You’re Jonas Salk, and you’re about to rid the world of polio.

It’s 2015, and you have the opportunity to invest in the company that is about to eliminate hepatitis B from the globe, once and for all.

All you have to do (IF YOU SO CHOOSE) is call your broker, and tell him to buy SVACF.

If You Do it today, you could get a 3,000% return on your money in just a few short years.

But more importantly, you could become an integral part of the saving of millions of lives.

This is one investment opportunity that in our opinion you cannot afford to miss. Not financially, maybe not even morally.



Who owns and controls the website located at

The website located at http// (the Website) is owned by MAPH Enterprises, LLC., a Florida corporation. The Website, its owner, affiliates, control persons, directors, officers, employees and agents are hereafter collectively referred to as the “Publisher”, “we”, “us” or “ours”.

What do we do?

We are paid advertisers, also known as stock touts or stock promoters who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”).

How is the Information published?

We publish the Information on the Website, in newsletters, audio, and live interviews featured reports message boards and email communications for specific time periods that are agreed upon between us and the Profiled Issuer. Our publication of the Information is known as a “Campaign”.

Will everyone receive the Information at the same time?

No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.

How is a potential investor impacted if they receive the Information later than other investors?

If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.

What will happen when the Campaign ends?

Most, if not, all of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide variations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will likely lose most, if not, all of their investment.

Why do we publish only favorable Information?

We only publish favorable information because we are compensated to only publish favorable information.

Why don’t we publish negative information?

We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.

Is the Information complete, accurate, truthful or reliable?

The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one sided and not balanced, complete, accurate, truthful or reliable.

What we do not do.

We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence or research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

Where does the Information come from?

The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources.

What will happen if an investor relies on the Information?

The Information is neither a solicitation to buy nor an offer to sell securities. The Information should not be used to make an investment decision or for trading or investment purposes. If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not, all of his or her investment.

Who pays us to publish the Information?

The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.

The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”.

What warranties do we make about the Information?

None. We make no warranty or representation about the Information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

Who is responsible if an investor relies on the Information?

The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information. A person’s review and/or reliance upon the Information is at their own risk. We are not responsible for omissions or errors in the Information. We will not update the Information and we are not responsible for actions taken by any person who relies upon the Information.

What do we urge potential investors to do?

Investors should conduct their own in-depth investigation of the Profiled Issuers with the assistance of his or her legal, tax and investment advisors. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information you and your advisors deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information you receive directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources.

Why is this Disclaimer being provided?

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 ( the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (“the “Securities Act”), to specifically disclose our compensation to you as well as other information including that we may hold, as well as purchase and sell the securities of a Profiled Issuer before, during and after we publish the Information about the Profiled Issuer. We may instruct investors to purchase the securities of a Profiled Issuer during the same time that we sell.

The anti-fraud provisions of state and federal securities laws require us to inform you that we will engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

What we are not.

We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:

What conflicts of interest do we have in publishing the Information?

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.

Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:

What are some of the risks that investors should be aware of?

Any investment in the Profiled Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers includes, but is not limited to the risks stated below.

Risks Related to the Profiled Issuers

Risks Related to buying the securities of the Profiled Issuers

Are risks in this disclaimer the only risks investors should be aware of?

No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax adviser prior to purchasing the securities of any Profiled Issuer.

What we were paid.

MAPH Enterprises LLC | was paid an advertising fee of $30,000 cash & ZERO shares by a non affiliate 3rd party share holder. for visual sponsorship on and for visual placement of SVCAF. within written materials. FOR A DURATION OF 30 DAYS BEGINNING 10/12/2015 - 11/12/2015